Teva, Sun to pay $2.15 billion to Pfizer, Takeda to settle Protonix case

Teva launched 'at-risk' generic in 2007

NEW YORK — Pfizer will receive more than $2 billion from Teva Pharmaceutical Industries and Sun Pharmaceutical Industries to settle a case concerning a gastroesophageal reflux disease drug.

The drug maker said Wednesday that Sun and Teva had agreed to pay $2.15 billion in a patent-infringement suit over the drug Protonix (pantoprazole). The money will compensate Pfizer and Takeda for damages they incurred when Teva and Sun launched "at-risk" generic versions of Protonix in 2007 before the 2011 expiration of a patent covering the drug. Teva will pay $1.6 billion, and Sun will pay $550 million; Pfizer will receive 64% of proceeds.

A federal jury in New Jersey determined that the launches violated U.S. Patent No. 4,758,576, owned by Takeda and licensed to Wyeth, which Pfizer acquired in 2009.

Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

Login or Register to post a comment.